Aprea heading for Phase III with €50M series C round

Aprea heading for Phase III with €50M series C round

Source: 
BioCentury
snippet: 

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic syndrome (MDS).